Are you Dr. Boxer?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 59 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
269 Campus Dr
Hematology Ccsr 1155
Stanford, CA 94305Phone+1 650-735-4036
Summary
- Dr. Linda Boxer, MD is an oncologist in Stanford, California. She is currently licensed to practice medicine in California. She is affiliated with Stanford Health Care, Lucile Packard Children's Hospital Stanford, and VA Palo Alto Heath Care.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1984 - 1985- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1981 - 1984
Stanford University School of MedicineClass of 1981
Certifications & Licensure
CA State Medical License 1982 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1996
Clinical Trials
- Anemia in the Elderly Start of enrollment: 2009 Aug 01
Publications & Presentations
PubMed
- 53 citationsPi 1 binding sites are negative regulators of bcl-2 expression in pre-B cells.Huei-Mei Chen, Linda M. Boxer
Molecular and Cellular Biology. 1995-07-01 - 67 citationsThe WT1 Protein Is a Negative Regulator of the Normalbcl-2 Allele in t(14;18) LymphomasCaroline A. Heckman, Evonne Mochon, Magdalena Arcinas, Linda M. Boxer
The Journal of Biological Chemistry. 1997-08-01 - 13 citationsIdentification of an inducible regulator of c-myb expression during T-cell activation.See-Chun Phan, Brian T. Feeley, D. Withers, Linda M. Boxer
Molecular and Cellular Biology. 1996-05-01
Press Mentions
Laurence “Larry” Kedes, Molecular Geneticist, Dies at 83April 26th, 2021- Children’s Hospital Los Angeles Chief Scientific Officer Named to California Stem Cell Research Body Governing BoardApril 7th, 2021
Grant Support
- Activation Of BCL-2 In Hematologic MalignanciesNational Cancer Institute2008–2011
- Training Program In Investigative HematologyNational Heart, Lung, And Blood Institute2004–2010
- Activation Of BCL-2 In Hematologic MalgnanciesNational Cancer Institute2007
- Activation Of BCL-2 In Hematologic MalignanciesNational Cancer Institute1993–2006
- Control Of C-MYC Transcription In High Grade LymphomaNational Cancer Institute2002–2005
- Molecular Studies Of Human AllNational Cancer Institute2001–2004
- Control Of MYC Transcription In High Grade LymphomaNational Cancer Institute2001
- Activation Of BCL 2 In Hematologic MalignanciesNational Cancer Institute1998–2001
- Regulation Of Expression Of C-MYB In LeukemiasNational Cancer Institute1996–2000
- Control Of C MYC Transcription In High Grade LymphomasNational Cancer Institute1996–2000
- Control Of C-MYC Transcription In Aggressive LymphomasNational Cancer Institute1996–1999
